Copyright Reports & Markets. All rights reserved.

Global Drug Repurposing Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Drug Repurposing

      • 1.1 Definition of Drug Repurposing
      • 1.2 Drug Repurposing Segment by Type
        • 1.2.1 Global Drug Repurposing Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 Oncology
        • 1.2.3 CNS Diseases
        • 1.2.4 Neurodegenerative Diseases
        • 1.2.5 Others
      • 1.3 Drug Repurposing Segment by Applications
        • 1.3.1 Global Drug Repurposing Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Hospitals
        • 1.3.3 Ambulatory Surgical Centers
        • 1.3.4 Others
      • 1.4 Global Drug Repurposing Overall Market
        • 1.4.1 Global Drug Repurposing Revenue (2014-2025)
        • 1.4.2 Global Drug Repurposing Production (2014-2025)
        • 1.4.3 North America Drug Repurposing Status and Prospect (2014-2025)
        • 1.4.4 Europe Drug Repurposing Status and Prospect (2014-2025)
        • 1.4.5 China Drug Repurposing Status and Prospect (2014-2025)
        • 1.4.6 Japan Drug Repurposing Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Drug Repurposing Status and Prospect (2014-2025)
        • 1.4.8 India Drug Repurposing Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Drug Repurposing
      • 2.3 Manufacturing Process Analysis of Drug Repurposing
      • 2.4 Industry Chain Structure of Drug Repurposing

      3 Development and Manufacturing Plants Analysis of Drug Repurposing

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Drug Repurposing Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Drug Repurposing
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Drug Repurposing Production and Capacity Analysis
      • 4.2 Drug Repurposing Revenue Analysis
      • 4.3 Drug Repurposing Price Analysis
      • 4.4 Market Concentration Degree

      5 Drug Repurposing Regional Market Analysis

      • 5.1 Drug Repurposing Production by Regions
        • 5.1.1 Global Drug Repurposing Production by Regions
        • 5.1.2 Global Drug Repurposing Revenue by Regions
      • 5.2 Drug Repurposing Consumption by Regions
      • 5.3 North America Drug Repurposing Market Analysis
        • 5.3.1 North America Drug Repurposing Production
        • 5.3.2 North America Drug Repurposing Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Drug Repurposing Import and Export
      • 5.4 Europe Drug Repurposing Market Analysis
        • 5.4.1 Europe Drug Repurposing Production
        • 5.4.2 Europe Drug Repurposing Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Drug Repurposing Import and Export
      • 5.5 China Drug Repurposing Market Analysis
        • 5.5.1 China Drug Repurposing Production
        • 5.5.2 China Drug Repurposing Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Drug Repurposing Import and Export
      • 5.6 Japan Drug Repurposing Market Analysis
        • 5.6.1 Japan Drug Repurposing Production
        • 5.6.2 Japan Drug Repurposing Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Drug Repurposing Import and Export
      • 5.7 Southeast Asia Drug Repurposing Market Analysis
        • 5.7.1 Southeast Asia Drug Repurposing Production
        • 5.7.2 Southeast Asia Drug Repurposing Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Drug Repurposing Import and Export
      • 5.8 India Drug Repurposing Market Analysis
        • 5.8.1 India Drug Repurposing Production
        • 5.8.2 India Drug Repurposing Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Drug Repurposing Import and Export

      6 Drug Repurposing Segment Market Analysis (by Type)

      • 6.1 Global Drug Repurposing Production by Type
      • 6.2 Global Drug Repurposing Revenue by Type
      • 6.3 Drug Repurposing Price by Type

      7 Drug Repurposing Segment Market Analysis (by Application)

      • 7.1 Global Drug Repurposing Consumption by Application
      • 7.2 Global Drug Repurposing Consumption Market Share by Application (2014-2019)

      8 Drug Repurposing Major Manufacturers Analysis

      • 8.1 Astellas Pharma
        • 8.1.1 Astellas Pharma Drug Repurposing Production Sites and Area Served
        • 8.1.2 Astellas Pharma Product Introduction, Application and Specification
        • 8.1.3 Astellas Pharma Drug Repurposing Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Biovista
        • 8.2.1 Biovista Drug Repurposing Production Sites and Area Served
        • 8.2.2 Biovista Product Introduction, Application and Specification
        • 8.2.3 Biovista Drug Repurposing Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Novartis
        • 8.3.1 Novartis Drug Repurposing Production Sites and Area Served
        • 8.3.2 Novartis Product Introduction, Application and Specification
        • 8.3.3 Novartis Drug Repurposing Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 AbbVie
        • 8.4.1 AbbVie Drug Repurposing Production Sites and Area Served
        • 8.4.2 AbbVie Product Introduction, Application and Specification
        • 8.4.3 AbbVie Drug Repurposing Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Pfizer
        • 8.5.1 Pfizer Drug Repurposing Production Sites and Area Served
        • 8.5.2 Pfizer Product Introduction, Application and Specification
        • 8.5.3 Pfizer Drug Repurposing Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 Allergan
        • 8.6.1 Allergan Drug Repurposing Production Sites and Area Served
        • 8.6.2 Allergan Product Introduction, Application and Specification
        • 8.6.3 Allergan Drug Repurposing Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 NuMedii
        • 8.7.1 NuMedii Drug Repurposing Production Sites and Area Served
        • 8.7.2 NuMedii Product Introduction, Application and Specification
        • 8.7.3 NuMedii Drug Repurposing Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served

      9 Development Trend of Analysis of Drug Repurposing Market

      • 9.1 Global Drug Repurposing Market Trend Analysis
        • 9.1.1 Global Drug Repurposing Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Drug Repurposing Regional Market Trend
        • 9.2.1 North America Drug Repurposing Forecast 2019-2025
        • 9.2.2 Europe Drug Repurposing Forecast 2019-2025
        • 9.2.3 China Drug Repurposing Forecast 2019-2025
        • 9.2.4 Japan Drug Repurposing Forecast 2019-2025
        • 9.2.5 Southeast Asia Drug Repurposing Forecast 2019-2025
        • 9.2.6 India Drug Repurposing Forecast 2019-2025
      • 9.3 Drug Repurposing Market Trend (Product Type)
      • 9.4 Drug Repurposing Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Drug Repurposing Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositioned. National Institute of Health (NIH), U.S. Department of Health defines drug repurposing as discovering new uses for approved drugs to provide the quickest possible transition from bench to bedside. Drug repurposing opens up various opportunities to answer current unmet medical needs to come up with cost-effective solutions to expensive drug development process. Repurposing or re-profiling of drugs which are suspended due to lack of efficacy or specificity can be a good start over for further development for new indication. Finding new indications for already studied drugs can benefit patients by getting quick access to new treatment choices and also to developer by saving time and money while maintaining its original IP protection. For many expensive indications such as cancer, scrutinizing for anti-cancer activity among dozens of off-patent drugs that have already established their safety is a powerful method opted by majority of the big pharma companies. However, repurposing is not a new strategy and there are bunch of drugs which are repositioned or repurposed, some of them are Raloxifene (approved for treatment of osteoporosis in 2007, originally indicated for breast cancer treatment), Thalidomide (repositioned for use in treatment of leprosy and multiple myeloma in 2006), Rapamycin (repurposed in 1999 for prevention of organ transplant rejection), Sildenafil (originally approved for erectile dysfunction and recently got approved for treatment of angina) and many others.
        Requirement of low investment of time and money in the drug development is the prime advantage of drug repurposing and majority of the drugs in pipeline of major pharmaceutical companies are thus adopt this method. Some of the factors accelerating the drug repurposing activities include sunk research cost, ready availably of bioavailability, pharmacology, toxicity profile & pharmacokinetics data, well established manufacturing protocol etc.; which are expected to drive the global drug repurposing market. There are thousands of failed molecules shelved into the drug libraries, which hold vast potential to reposition. Whereas, limited access chemical structure data of drug molecules, lack of funding etc. are some of the factors limiting the growth of global drug repurposing market.

        The global Drug Repurposing market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
        This report focuses on Drug Repurposing volume and value at global level, regional level and company level. From a global perspective, this report represents overall Drug Repurposing market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Drug Repurposing in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Drug Repurposing manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Astellas Pharma
        Biovista
        Novartis
        AbbVie
        Pfizer
        Allergan
        NuMedii
        ...

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        Oncology
        CNS Diseases
        Neurodegenerative Diseases
        Others

        Segment by Application
        Hospitals
        Ambulatory Surgical Centers
        Others

        Buy now